Nasdaq GlobeNewswire

Motif Bio Reports Year-End 2016 Financial Results


NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2016.

"Motif Bio made significant progress in 2016 towards our goal of bringing our novel antibiotic candidate, iclaprim, to patients with serious and life-threatening infections. The announcement of positive Phase 3 topline results for iclaprim in REVIVE-1 was a major achievement for Motif Bio and we expect to announce the topline data from REVIVE-2, the second Phase 3 trial, in the second half of 2017," commented Graham Lumsden, CEO of Motif Bio plc. 

Recent Corporate Developments

  • Announced positive topline results for iclaprim in the REVIVE-1 Phase 3 study of acute bacterial skin and skin structure infections (ABSSSI)
  • Data from REVIVE-2, which uses an identical protocol to REVIVE-1 but has different trial centres, has more than 80% of the total patients enrolled, and data is expected in the second half of 2017
  • Achieved a NASDAQ listing
  • Closed a U.S. initial public offering and a concurrent European placement with aggregate net proceeds of $21.5 million, which brought the total raised by the Company to approximately $65 million 
  • Appointed Robert Dickey IV as Chief Financial Officer
  • Presented two posters at ID Week 2016. The first showed new data demonstrating that iclaprim is highly potent in vitro against bacterial strains associated with clinical Hospital Associated Bacterial Pneumonia (HABP) and Skin and Skin Structure Infections (SSSI) clinical isolates. The second poster described the potential benefits of an optimized 80mg fixed dose of iclaprim administered intravenously over 120 minutes, that is being used in the REVIVE Phase 3 clinical trials. Improvement by approximately 30% in the PK/PD parameters associated with efficacy, AUC/MIC and t/MIC, was seen compared to the previously studied weight based dose of 0.8 mg/kg.
  • Completed preparations for INSPIRE, a Phase 3 trial designed to study the safety and efficacy of iclaprim in patients with HABP, including ventilator associated bacterial pneumonia (VABP)
  • Completed additional research with clinicians and payers to understand how iclaprim may be able to address the unmet need in hospitalised ABSSSI patients with renal impairment with/without diabetes

Full Year 2016 Financial Results

  • For the full year, Motif Bio reported a net loss of $40.3 million, or $(0.35) per share (basic and diluted) compared to a net loss of $8.5 million, or $(0.14) per share (basic and diluted) during the same period in 2015.
  • Research and development (R&D) costs for 2016 were $34.8 million compared to $4.7 million during 2015. Higher R&D costs in 2016 were primarily attributable to the commencement of iclaprim clinical development. Clinical development expenses are a significant component of our research and development expenses and product candidates in later stage development generally have higher costs.
  • General and administrative expenses for 2016 were $4.9 million compared to $3.6 million during 2015. The increase is primarily due to the costs associated with the filing of a registration statement relating to the initial public offering in the U.S.; costs associated with being a public company in both the United Kingdom and the U.S.; and increases in the costs of outside professional services.
  • Cash and cash equivalents were $21.8 million as of December 31, 2016.
  • As of December 31, 2016, the Company had 195.7 million ordinary shares outstanding.

Motif Bio has filed its U.S. Annual Report on Form 20-F for the year ended December 31, 2016 with the US Securities and Exchange Commission ("SEC"). The Form 20-F is available to download, either from the Investors section of the Company website at, the SEC website at or from the link below.

Click here to download the Form 20-F

About iclaprim
Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics, including trimethoprim. Iclaprim exhibits potent in vitro activity against Gram-positive clinical isolates of many genera of staphylococci, including methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA). The MIC90 of iclaprim was lower than most comparators including vancomycin and linezolid, standard of care therapies used in serious and life-threatening Gram-positive hospital infections. To date, iclaprim has been studied in over 1,000 patients and healthy volunteers. Iclaprim is administered intravenously at a fixed dose, with no dosage adjustment required in patients with renal impairment, or in obese patients. This may help reduce overall hospital treatment costs, especially in renally impaired patients.

About Motif Bio plc Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.

Forward-Looking Statements 
This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio's product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio's product candidates, (iii) Motif Bio's ability to successfully commercialize its product candidates, (iv) Motif Bio's ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio's commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio's expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio's product candidates, (viii) Motif Bio's ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, and (ix) Motif Bio's estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled "Risk Factors" in Motif Bio plc's Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SEC's web site, Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.

"This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 and has been released by Robert Dickey IV, Chief Financial Officer, on behalf of the Company."

For further information please contact:

Motif Bio plc
Graham Lumsden (Chief Executive Officer)  
Robert Dickey IV (Chief Financial Officer)  
Peel Hunt LLP (NOMAD & BROKER) + 44 (0)20 7418 8900
Dr Christopher Golden  
Oliver Jackson  
Northland Capital Partners Limited (BROKER) +44 (0)203 861 6625
Patrick Claridge/ David Hignell  
John Howes/ Rob Rees (Broking)  
Westwicke Partners 001 415-513-1284
Patricia L. Bank
Walbrook PR Ltd. (FINANCIAL PR & IR) +44 (0) 20 7933 8780 or
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN IR) +49 (0)89 210 2280

Motif Bio plc Selected Financial Data

          US $
      US $
      US $
  Continuing operations              
  General and administrative expenses     (4,912,150 )       (3,577,180 )       (1,096,116 )
  Research and development expenses     (34,794,815 )       (4,680,940 )      -   
  Gains on settlement of contract disputes     83,320         5,027         360,060  
  Operating loss         (39,623,645 )       (8,253,093 )       (736,056 )
  Interest income         69,754         15,028         78  
  Interest expense         (383,259 )       (268,216 )       (449,036 )
  Net foreign exchange losses       (250,926 )       (9,644 )      -   
  Loss from revaluation of derivative liabilities     (135,939 )       -          -   
  Loss before income taxes         (40,324,015 )       (8,515,925 )       (1,185,014 )
  Income tax         (287 )       (774 )       (876 )
  Net loss for the year         (40,324,302 )       (8,516,699 )       (1,185,890 )
  Total comprehensive loss for the year     (40,324,302 )       (8,516,699 )       (1,185,890 )
  Net loss per share              
  Basic and diluted per share *   $   (0.35 )   $   (0.14 )   $   (0.03 )
  Weighted average number of ordinary  shares, basic and diluted     116,558,191       61,225,922       36,726,342  
  *   In accordance with IAS 33 "Earnings per share", shares are not diluted where the entity has reported a loss for the period.

    December 31, 2016     December 31, 2015  
    US $     US $  
Non-current assets        
Intangible assets     6,195,748       6,195,748  
Total non-current assets     6,195,748       6,195,748  
Current assets        
Prepaid expenses and other receivables   401,064       167,657  
Cash      21,829,632       28,594,347  
Total current assets     22,230,696       28,762,004  
Total assets     28,426,444       34,957,752  
Non-current liabilities        
Payable on completion of clinical trial   -        500,000  
Total non-current liabilities     -        500,000  
Current liabilities        
Trade and other payables     12,319,117       987,083  
Other interest-bearing loans and borrowings   -        3,747,961  
Derivative liability     5,798,058       -   
Payable on completion of clinical trial   500,000       -   
Total current liabilities     18,617,175       4,735,044  
Total liabilities     18,617,175       5,235,044  
Net assets     9,809,269       29,722,708  
Share capital   2,728,199     1,645,291  
Share premium   57,348,694     38,534,280  
Group reorganization reserve     9,938,362       9,938,362  
Accumulated deficit     (60,205,986 )     (20,395,225 )
Total equity     9,809,269       29,722,708  

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Motif BioSciences Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Comodo CA Sees 35 Percent Year-Over-Year Increase in EV Certificates22.3.2018 15:47Pressemelding

EV SSL will be a topic of discussion at the Comodo CA booth during RSA 2018 CLIFTON, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, will address evolving cyberthreats and the increasing importance Extended Validation (EV) TLS/SSL certificates play in securing websites and inspiring consumer trust at the RSA Conference 2018, San Francisco, April 16 - 20. According to the Feb 2018 Netcraft report, Comodo CA has seen a 35 percent year-over-year increase of EV certificate units* making it one of the fastest growing providers of high assurance certificates. The volume of EV certificates globally also saw a record year in 2017 as more and more businesses adopt EV as standard practice for their websites. The demand for stronger, more secure EV certificates comes in the wake of increased phishing websites using Domain Validated (DV) certificates. Phishing websites imitate legitimate websites to steal customers' funds and identities. Phishi

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody22.3.2018 14:43Pressemelding

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies. The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. Under the terms of this global licensing agreement, CBT gain

Cloudflare Announces Mobile SDK to Monitor Network Performance for Applications22.3.2018 14:00Pressemelding

New free solution delivers network analytics to any mobile app developer SAN FRANCISCO, March 22, 2018 (GLOBE NEWSWIRE) -- Cloudflare, the leading Internet performance and security company, today announced the Cloudflare Mobile SDK, a free solution that enables any mobile app developer to understand network performance and metrics. Consumers are frustrated by mobile apps that are slow, crash, or deliver errors that degrade the user experience. For mobile app developers, a bad user experience means poor reviews, lower engagement, and reduced conversion on business metrics. Delivering consistent app performance requires focusing on every link in the chain: app code, network calls between the app and edge networks, and server infrastructure. There are a number of solutions that give developers analytics on their applications, but there has never been a way for app developers to understand how often their apps fail due to network errors. App developers easily integrate the Cloudflare Mobil

Compuware: Survey Shows Critical Mainframe Workloads Increasing While Mainframe Staff Losses Remain Unfilled22.3.2018 13:00Pressemelding

Many Organizations Not Measuring, Prioritizing Vital Key Performance Indicators 57 percent of enterprises with a mainframe currently run more than half of their business-critical applications on the platform-with that number expected to increase to 64 percent by next year. 72 percent of customer-facing applications are completely or very dependent on mainframe processing. Enterprises have only replaced 37 percent of the mainframe workforce lost over the past five years. Many organizations surveyed are not currently measuring velocity or efficiency key performance indicators, putting them at a disadvantage in the digital age. DETROIT, March 22, 2018 (GLOBE NEWSWIRE) -- The mainframe is becoming more important to large enterprises, with the percentage of organizations running at least half their business-critical applications on that platform expected to increase next year. However, the loss of skilled mainframe staff, and the failure to subsequently fill these positions, pose significan

SEMAFO: Construction of Boungou Mine 87% Complete22.3.2018 12:00Pressemelding

Dry Plant Commissioning Underway MONTREAL, March 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) is pleased to announce that construction of the Boungou Mine in Burkina Faso is 87% complete, with first gold scheduled to be poured early in the third quarter of 2018. In a first step towards this milestone, the Corporation began commissioning activities on dry plant equipment this week. All amounts are in US dollars unless otherwise stated. Over the coming weeks, as construction continues, the crushing and reclaim circuit equipment required for initial production will undergo testing. The power plant, which was over 90% complete at the end of February, has been partially operational since early March. As at February 28, 2018, the additional key achievements had been made: Development on budget with US$182 million of the US$231 million capital expenditure incurred Construction of the mine 87% complete Completion of some 94% of structural steel and mechanical installation Pipin

Lexin Appoints Two New Directors to Expand Board22.3.2018 02:49Pressemelding

SHENZHEN, China, March 22, 2018 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), a leading online consumer finance platform for educated young adults in China, today announced the appointment of Dr. Neng Wang as an independent director of the Company's board of directors (the "Board"), and the appointment of Mr. Xiaoguang Wu as a director of the Board, effective on March 20, 2018. These two appointments have expanded the Board to eight members, from six previously. Dr. Wang is also serving as a member of the audit committee, the compensation committee and the nominating and corporate governance committee of the Board. Dr. Wang has replaced Mr. Keyi Chen, Mr. Jared Yi Wu, and Mr. Yibo Shao respectively from the abovementioned committees of the Board, all of whom remain as directors on the Board. Dr. Wang has been Chong Khoon Lin Professor of Real Estate at Columbia Business School since July 2007, and a research associate at the National Bureau of E

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom